Outlook Therapeutics
0 followers
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.
Org chart
C. Russell Trenary III
President & CEO
C. Russell Trenary III
Collapse
Terry Dagnon
COO
Jeff Evanson
Chief Commercial Officer
Anu Wallecha
Associate Director, Bioassay Development
Entisar Dahan, MPM, PHR
Director Human Resources
Jennifer Kissner
Senior Vice President, Clinical & Regulatory Affairs
Kathleen Billman
Executive Director, Clinical Affairs
Lauren Nelson
Executive Director, Patient Access & Marketing
Christoph Puetz
Head Of Information Technology Department
Surendra Sharma
Senior Vice President, Medical Affairs
Tony Moses
Executive Director of Physician Relations
